Yusheng Han Purchases 210,000 Shares of Burning Rock Biotech (NASDAQ:BNR) Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 210,000 shares of the stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $9.25 per share, with a total value of $1,942,500.00. Following the purchase, the director owned 17,907,436 shares of the company’s stock, valued at $165,643,783. This trade represents a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.00 per share, for a total transaction of $999,990.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of BNR opened at $8.96 on Thursday. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.22 and a twelve month high of $41.72. The firm’s fifty day simple moving average is $12.79 and its 200-day simple moving average is $20.08. The firm has a market capitalization of $94.26 million, a price-to-earnings ratio of -10.93 and a beta of 1.33. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last posted its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Analyst Ratings Changes

A number of research firms recently issued reports on BNR. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On Burning Rock Biotech

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its holdings in Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Burning Rock Biotech during the 4th quarter valued at approximately $220,000. Crcm LP boosted its stake in shares of Burning Rock Biotech by 121.8% during the 4th quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after acquiring an additional 269,851 shares in the last quarter. Finally, Prospera Financial Services Inc boosted its stake in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after acquiring an additional 6,430 shares in the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.